Marekani - Kiingereza - NLM (National Library of Medicine)

physicians total care, inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline mesylate 1 mg - azilect (rasagiline tablets) is indicated for the treatment of the signs and symptoms of idiopathic parkinson's disease as initial monotherapy and as adjunct therapy to levodopa. the effectiveness of azilect was demonstrated in patients with early parkinson's disease who were receiving azilect as monotherapy and who were not receiving any concomitant dopaminergic therapy. the effectiveness of azilect as adjunct therapy was demonstrated in patients with parkinson's disease who were treated with levodopa. enter section text here azilect is contraindicated for use with meperidine. serious adverse reactions have been precipitated with concomitant use of meperidine (e.g., demerol and other tradenames) and mao inhibitors (maois) including selective mao-b inhibitors. these adverse reactions are often described as "serotonin syndrome", a potentially serious condition, which can result in death. typical clinical signs and symptoms include behavioral and cognitive/mental status changes (e.g., confusion, hypomania

Marekani - Kiingereza - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline 1 mg - azilect (rasagiline tablets) is indicated for the treatment of parkinson’s disease (pd). azilect is contraindicated for use with meperidine, tramadol, methadone, propoxyphene and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)] . at least 14 days should elapse between discontinuation of azilect and initiation of treatment with these medications. azilect is contraindicated for use with st. john’s wort and with cyclobenzaprine. azilect is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. pregnancy category c there are no adequate and well-controlled studies of rasagiline in pregnant women. azilect should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in a combined mating/fertility and embryo-fetal development study in pregnant rats, no effect on embryo-fetal development was observed at oral doses up to 3 mg/kg/da

Marekani - Kiingereza - NLM (National Library of Medicine)

teva neuroscience, inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline 0.5 mg - azilect (rasagiline tablets) is indicated for the treatment of parkinson’s disease (pd). azilect is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)] . at least 14 days should elapse between discontinuation of azilect and initiation of treatment with these medications. azilect is contraindicated for use with st. john’s wort and with cyclobenzaprine. azilect is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. risk summary there are no adequate data on the developmental risks associated with the use of azilect in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinically. when administered to pregnant animals in combination

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet - excipient ingredients: stearic acid; purified talc; mannitol; colloidal anhydrous silica; maize starch; pregelatinised maize starch - azilect is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Israeli - Kiingereza - Ministry of Health

inovamed ltd - rasagiline as hemitartrate - tablets - rasagiline as hemitartrate 1 mg - rasagiline - rasagiline inovamed is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations

Israeli - Kiingereza - Ministry of Health

teva israel ltd - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Israeli - Kiingereza - Ministry of Health

teva pharmaceutical industries ltd, israel - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Israeli - Kiingereza - Ministry of Health

teva pharmaceutical industries ltd, israel - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Malta - Kiingereza - Medicines Authority

ascend gmbh c/o pollux business center gmbh sebastian-kneipp-straße 41, 60439 frankfurt am main, germany - tablet - rasagiline 1 mg - anti-parkinson drugs

Israeli - Kiingereza - Ministry of Health

trima israel pharmaceutical products maabarot ltd - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.